Cosimprel (bisoprolol/perindopril) / Servier - LARVOL DELTA

Preventing Cardiomyopathy in Duchenne Muscular Dystrophy: Long-Term Follow-Up of Patients in the Randomised, Placebo-Controlled Drug-Trial of Perindopril and Bisoprolol. (PubMed, Eur J Neurol) - "While some patients may have benefited from 'early' (active) as opposed to 'delayed' (placebo) initiation of perindopril and bisoprolol, group-mean ventricular function did not differ between study arms after 60 months. Small numbers, absence of a control group, insensitivity of echo-ejection fraction, and additional drug use probably prevented divergence between groups."

Clinical • Journal • Cardiomyopathy • Cardiovascular • Duchenne Muscular Dystrophy • Genetic Disorders • Heart Failure • Muscular Dystrophy

Takotsubo syndrome in a cancer patient treated with a combination of anti-cancer drugs including immune checkpoint inhibitors: a case report. (PubMed, Eur Heart J Case Rep) - "She had previously received osimertinib as first-line therapy for recurrent lung cancer after primary resection and atezolizumab in combination with bevacizumab, paclitaxel, and carboplatin as second-line therapy...Atypical TTS was suspected, and she was treated with perindopril, bisoprolol, and spironolactone. Magnetic resonance imaging 1.5 months after the onset of TTS showed improvements in LV contractility, T1 and T2 values, and the extracellular volume fraction. A more detailed understanding of the relationship between anti-cancer drugs and TTS is crucial for preventing interruptions to anti-cancer therapy."

Checkpoint inhibition • Journal • Cardiovascular • Lung Cancer • Myocardial Infarction • Oncology • Pulmonary Disease • Solid Tumor

MELANOMA AND DYSPLASTIC NEVI DEVELOPMENT AFTER RANITIDINE/RILMENIDINE/МOXONIDINE, LERCANIDIPINE, ROSUVASTATIN AND VERAPAMIL/TRANDOLAPRIL - NEW DATA/CASE SERIES. THE POTENTIAL ROLE OF NITROSAMINE/NDSRIS CONTAMINATION IN POLYMEDICATION AS SUBSTANTIAL SKIN CANCER TRIGGERING FACTOR. (PubMed, Georgian Med News) - "In the last decade, melanoma has been described repeatedly in the medical literature as a possible side-effect within the intake of possibly with nitrosamines contaminated medications such as: Valsartan, Hydrochlorothiazide, Amlodipine, Nebivolol, Bisoprolol and Perindopril. Ingredients that are present in drug preparations, identified as availability and as carcinogenic potency, but not yet reflected in packaging or prescriptions. The question remains: why?"

Journal • Cutaneous Melanoma • Genetic Disorders • Melanoma • Oncology • Skin Cancer • Solid Tumor

Drug-induced oesophagitis mimicking oesophageal neoplasia (BWG 2024) - "His current medication included acetylcysteine, bisoprolol, perindopril, amlodipine, atorvastatin, edoxaban, bumetanide, moxonidine and spironolactone...In our case, aspirin or blood pressure-lowering drugs were most likely the responsible for this pill-induced oesophagitis (1-4)... This case calls attention to include pill induced oesophagitis in the differential diagnosis in patients presenting with odynophagia, dysphagia, retrosternal chest pain and potentially upper GI bleeding. The cornerstone is to exclude other diagnosis like oesophageal malignancy with upper GI endoscopy and histopathological examination. Pill induced oesophagitis has an excellent prognosis following conservative treatments, as demonstrated in our case with complete resolution of the initial severe presentation."

Anorexia • Cardiovascular • Coronary Artery Disease • Esophageal Cancer • Gastrointestinal Cancer • Gastrointestinal Disorder • Heart Failure • Oncology • Pain • Peripheral Arterial Disease • Thrombosis

A Retrospective Observational Real-Word Analysis of the Adherence, Healthcare Resource Consumption and Costs in Patients Treated with Bisoprolol/Perindopril as Single-Pill or Free Combination. (PubMed, Adv Ther) - "In a real-world setting, patients treated with PER/BIS SPC showed higher adherence, lower risk of drug discontinuation, reduced risk of CV hospitalization, and lower healthcare costs than those on FEC of the same drugs."

Adherence • Journal • Retrospective data • Cardiovascular

Effectiveness and Tolerability of Bisoprolol/Perindopril Single-Pill Combination in Patients with Arterial Hypertension and a History of Myocardial Infarction: The PRIDE Observational Study. (PubMed, Adv Ther) - P=N/A | "Treatment of symptomatic patients with CAD, hypertension, and a history of MI with a bisoprolol/perindopril SPC was associated with significant decreases in SBP/DBP and a high proportion of patients achieving BP treatment goals. This was accompanied by improvements in angina symptoms and reductions in HR in a broad patient population representative of those seen in everyday clinical practice."

Journal • Observational data • Cardiovascular • Coronary Artery Disease • Hypertension • Myocardial Infarction • Pulmonary Arterial Hypertension

Prevention of Cardiovascular Diseases Caused by Complex Treatment of Patients With Primary Operated Breast Cancer (clinicaltrials.gov) - P2 | N=100 | Completed | Sponsor: State Institution "Republican Scientific and Practical Center" Cardiology, Belarus | Recruiting ➔ Completed | Trial completion date: Jun 2024 ➔ Feb 2023 | Trial primary completion date: Jun 2022 ➔ Feb 2023

Trial completion • Trial completion date • Trial primary completion date • Breast Cancer • Cardiovascular • Oncology • Solid Tumor

EFFECTIVENESS AND TOLERABILITY OF BISOPROLOL/PERINDOPRIL SINGLE-PILL COMBINATION IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE AND CONCOMITANT HYPERTENSION WHO HAD A HISTORY OF MIOCARDIAL INFARCTION. (PubMed, J Hypertens) - P=N/A | "In stable CAD patients with HTN and a history of MI treated with Bis/Per SPC for 3 months, significant improvement in BP and HR control, reduced angina attacks and SAN intake were observed, and treatment was well tolerated."

Journal • Cardiovascular • Coronary Artery Disease • Hypertension • Myocardial Infarction

CLINICAL EFFICACY AND SAFETY OF AMLODIPINE/BISOPROLOL/PERINDOPRIL SINGLE-PILL AND FREE COMBINATION THERAPY IN PATIENTS WITH UNCONTROLLED ESSENTIAL HYPERTENSION. (PubMed, J Hypertens) - "In case of uncontrolled BP despite monotherapy at maximal dose or bitherapy at initial dose, switching to triple therapy of amlodipine 5mg+bisoprolol 5mg+perindopril 5 mg leads to a significant decrease of BP (p < 0.001), an improvement of response to treatment and better BP control rate. For similar efficacy, treatment by SPC showed lower rate of treatment-related adverse events and was assessed as more convenient by patients as compared to free combination."

Combination therapy • Journal • Cardiovascular • Hypertension

PRIDE. Assessment of the Efficacy, Adherence and Tolerability of the Single Pill Combination Bisoprolol/Perindopril (clinicaltrials.gov) - P=N/A; N=486; Completed; Sponsor: Servier Russia; Recruiting ➔ Completed; Trial completion date: Jan 2022 ➔ Oct 2021

Clinical • Trial completion • Trial completion date • Cardiovascular • Coronary Artery Disease • Hypertension • Myocardial Infarction • Pulmonary Arterial Hypertension

Preventing Cardiomyopathy in DMD: A Randomized Placebo-Controlled Drug Trial. (PubMed, Neurol Clin Pract) - "Consistent with the previous prophylactic perindopril heart study, there was no evidence of group benefit after 36-month treatment. This study provides Class I evidence that combination perindopril-bisoprolol therapy was well tolerated but did not change decline in LVEF significantly in boys with DMD."

Clinical • Journal • Cardiomyopathy • Cardiovascular • Duchenne Muscular Dystrophy • Genetic Disorders • Muscular Dystrophy

Advanced chemometric methods as powerful tools for impurity profiling of drug substances and drug products: Application on bisoprolol and perindopril binary mixture. (PubMed, Spectrochim Acta A Mol Biomol Spectrosc) - "Three advanced, accurate and precise chemometric methods were developed as impurity profiling methods for a mixture of bisoprolol fumarate (BIS) and perindopril arginine (PER) with their degradation products which represent drug impurity or a precursor to such impurity. The designed models were able to predict the concentrations of the drugs and the degradation products/impurities in the validation set and pharmaceutical formulation. The proposed methods presented a powerful alternative to traditional and expensive chromatographic methods as impurity profiling tools."

Journal

Concomitant Treatment of Hypertensive Patients with Bisoprolol and Perindopril in Routine Clinical Practice: A Post Hoc Analysis of the CONFIDENCE II, PROTECT I, and PROTECT III Observational Studies. (PubMed, Adv Ther) - "The addition of perindopril on top of bisoprolol-based therapy in patients with mild-to-moderate hypertension was associated with significant reductions in BP compared with baseline and with achievement of BP targets in the majority of patients. The results suggest this strategy is safe and effective for use in routine clinical practice."

Clinical • Journal • Observational data • Retrospective data • Cardiovascular • Coronary Artery Disease • Hypertension

The Combination of Beta-Blockers and ACE Inhibitors Across the Spectrum of Cardiovascular Diseases. (PubMed, Cardiovasc Drugs Ther) - "This paper examines the supporting evidence for beta-blockers and ACE inhibitors in each of the above indications and considers the rationale for combining these agents into a single pill, using data from bisoprolol and perindopril randomized controlled trials as supporting evidence. Combining these established antihypertensive agents into a single pill continues to provide effective blood pressure lowering and improved cardiovascular outcomes while allowing a greater proportion of patients to rapidly achieve treatment targets."

Journal • Review • Acute Coronary Syndrome • Atrial Fibrillation • Cardiovascular • Congestive Heart Failure • Coronary Artery Disease • Heart Failure • Hypertension

Optimization of localized surface plasmon resonance hot spots in surface-enhanced infrared absorption spectroscopy aluminum substrate as an optical sensor coupled to chemometric tools for the purity assay of quinary mixtures. (PubMed, Mikrochim Acta) - "These substrates were coupled to partial least squares regression tools for simultaneous resolving of the quinary mixture in commercial dosage forms of bisoprolol, perindopril, bisoprolol acid degradation product, bisoprolol alkali degradation product, and perindoprilat in concentration ranges of 15-75, 60-300, 15-55, 12-60, and 20-80 μg/mL with limits of detection values of 0.69, 3.43, 0.97, 1.25, and 1.09 μg/mL, respectively. Overall, we could demostrate that the localized surface plasmon resonance sensor coupled to chemometrics provides cheap, simple, selective, multiplex, rapid, and molecular specific procedures for impurity detection, which would be beneficial in many applications for quality control and quality accuracy of active pharmaceutical ingredients."

Journal

Effectiveness and Tolerability of the Single-Pill Combination of Bisoprolol and Perindopril in Patients with Arterial Hypertension and Stable Coronary Artery Disease in Daily Clinical Practice: The STYLE Study. (PubMed, Adv Ther) - P=N/A | "Treatment of patients with hypertension and CAD with Bis/Per SPC for 3 months was associated with significant decreases in SBP/DBP and a high proportion of patients achieving BP treatment goals. This was accompanied by an improvement in angina symptoms. Treatment was well tolerated in a broad patient population representative of those seen in everyday clinical practice."

Clinical • Journal • Cardiovascular • Coronary Artery Disease • Hypertension • Pulmonary Arterial Hypertension

PRIDE. Assessment of the Efficacy, Adherence and Tolerability of the Single Pill Combination Bisoprolol/Perindopril (clinicaltrials.gov) - P=N/A; N=500; Recruiting; Sponsor: Servier Russia; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Cardiovascular • Coronary Artery Disease • Hypertension • Myocardial Infarction • Pulmonary Arterial Hypertension

STYLE: Assessment of the Efficacy and Tolerability of the Fixed-dose Combination of Bisoprolol/Perindopril (clinicaltrials.gov) - P=N/A; N=1909; Completed; Sponsor: Servier Russia; Recruiting ➔ Completed

Clinical • Trial completion • Cardiovascular • Coronary Artery Disease • Heart Failure • Hypertension • Pulmonary Arterial Hypertension

Prestilol(Perindopril+Bisoprolol) in Therapy of Patients With Atrial Fibrilation (clinicaltrials.gov) - P; N=50; Not yet recruiting; Sponsor: Aversi Clinic

Clinical • New trial • Atrial Fibrillation

STYLE: Assessment of the Efficacy and Tolerability of the Fixed-dose Combination of Bisoprolol/Perindopril in Patients With Arterial Hypertension and Stable CAD in Daily Clinical Practice (clinicaltrials.gov) - P=N/A; N=1920; Recruiting; Sponsor: Servier Russia; Trial primary completion date: Mar 2019 ➔ Jan 2020

Clinical • Trial primary completion date

STYLE: Assessment of the Efficacy and Tolerability of the Fixed-dose Combination of Bisoprolol/Perindopril in Patients With Arterial Hypertension and Stable CAD in Daily Clinical Practice (clinicaltrials.gov) - P=N/A; N=1920; Recruiting; Sponsor: Servier Russia; Trial completion date: Feb 2019 ➔ Jan 2020

Clinical • Trial completion date